Several studies have reported a poor outcome with cardiac resynchronization therapy (CRT) in non-left bundle branch block (LBBB) patients. Although the left ventricular (LV) lead location is an important determinant of the clinical outcome, there is scant information regarding its role in non-LBBB patients. This study sought to examine the impact of electrical and anatomical location of the LV lead in relation to baseline QRS morphology on the CRT outcome.
Introduction
Cardiac resynchronization therapy improves morbidity, mortality, and reverse remodelling in medically refractory, congestive heart failure patients. 1 -5 Several studies have identified multiple determinants of response to CRT of which QRS duration and morphology 6 along with LV lead location 7 have been noted to be clinically significant. Most prior work has demonstrated that patients with a left bundle branch block (LBBB) configuration have a high likelihood of responding favourably to CRT. 8 This is based on the contention that the conventional LV lead placement strategy along the free lateral wall of the left ventricle most often targets the anatomical region of the heart that is the latest activation segment in a classic LBBB activation pattern. 9, 10 Further subgroup analysis of these clinical trials and several observational studies have reported a lack of benefit of CRT in non-LBBB patients, 11 consequently questioning its use and the conventional LV lead implantation approach in this group. 6 Most recently, it has been suggested that the placement of left ventricular lead over a region of the heart with delayed electrical activation may improve reverse remodelling and clinical outcome. It has also been observed that this approach is of additional value over conventional anatomical placement of the LV lead. It is however unclear whether this benefit is observed across all QRS morphologies (i.e. LBBB and non-LBBB). The objective of this study was to ascertain if intra-procedural identification of an optimal LV pacing site using the 'electrical delay' approach may help predict an improved clinical response among patients with LBBB and non-LBBB QRS morphologies.
Methods

Patient cohort
The study population was derived from 180 consecutive patients, who met the standard criteria for CRT at the time of implantation: reduced LV systolic function (EF ,35%), QRS duration .120 ms, and symptomatic heart failure despite maximal medical therapy, and had intraprocedural LVLED measurements during the CRT device implantation from April 2003 to December 2011. This is a single-centre study where all patients were enrolled in a prospective database and followed in a multidisciplinary clinic. 12 Thirty-six patients with baseline RV pacing were eliminated from the study. The analysis focused on a total of 144 patients, comparing non-LBBB (n ¼ 62) to LBBB (n ¼ 82). The LV lead was implanted via the transvenous approach in all patients. Coronary sinus venography was performed in left anterior oblique and right anterior oblique views to adequately assess coronary venous anatomy. Left ventricular lead was implanted in the most favourable location based on the availability of a suitable target vein, acceptable pacing thresholds without diaphragmatic stimulation and lead stability. Site selection was primarily based on anatomical location, although since 2006, an attempt to place the lead in a region of an electrical delay was often made proactively by the implanting physicians. Post-implantation, the patients after 2006 were followed in a multidisciplinary clinic, where subsequent clinical data were collected prospectively. Notably, three physicians reviewed baseline ECGs to assess QRS morphology 13 and disagreements were resolved by consensus.
Determination of left ventricular lead location and left ventricular electrical delay
Left ventricular lead location was adjudicated by reviewing coronary venous angiography and chest radiographs by a physician who was blinded to clinical outcomes (J.K./J.P.S.). Left ventricular lead location was classified as anterior, anterolateral, lateral, posterolateral, and posterior in the short-axis view and basal, mid-ventricular, and apical in long-axis view. This classification has been validated in the prior studies. 14, 15 To assess an intra-procedural left ventricular lead electrical delay (LVLED), simultaneous recording of surface ECG and sensed LV electrogram during the intrinsic rhythm were obtained. The LVLED was measured in milliseconds from QRS onset on surface ECG to the peak of sensed LV electrogram and expressed as a percentage of QRS duration (Figure 1) . The electrical delay not corrected to QRS duration was called QLV. In all cases, the limb lead with the best defined and widest QRS signal on the ECG strip recorded at a speed of 50 mm/s from the programmer was used to calculate QRS duration. All the measurements were made electronically using Cardio Calipers ver. 3.3 (Iconico Software, New York, NY, USA).
Clinical follow-up
Since 2006, all patients were followed in a multidisciplinary CRT clinic that includes providers from the electrophysiology, imaging, and heart failure divisions. All patients uniformly underwent echocardiography-guided AV and VV interval optimization at 1 month after implant. 12 Titration and optimization of medications was performed at the discretion of the treating physicians. The primary clinical endpoint was time to first HFH and the secondary clinical endpoint was a composite of all-cause mortality, HFH, left ventricular assist device (LVAD) implantation, and cardiac transplantation; and change in the left ventricular ejection fraction (LVEF). Heart failure hospitalization was defined as inpatient admission with signs or symptoms of heart failure, including shortness of breath, peripheral oedema, or congestion on the chest radiograph; and then improvement of these signs and/or symptoms with medical therapy. Baseline characteristics, echocardiographic variables were collected prospectively during office visits while clinical outcome data were collected by reviewing medical records. The social security death index was also searched for mortality data.
Transthoracic echocardiography (TTE) was performed at baseline prior to CRT device implantation and at the 12-month CRT clinic visit. All echocardiograms were performed on commercial ultrasound machines (Philips iE33, SONOS 5500/7500, Andover, MA, USA and General Electric Vivid 7, Milwaukee, WI, USA). Left ventricle end-diastolic and end-systolic dimensions were measured from the parasternal long-axis view. The left ventricle ejection fraction was calculated by following the standard biplane method of discs from the apical four-and two-chamber views. Echocardiographic variables collected were the LVEF, left ventricular internal diameter in diastole (LVIDd), and left ventricular internal diameter in systole (LVIDs). Of note, echocardiographic response to CRT was defined as an increase in the LVEF by 10% or greater. 
LV lead electrical delay and QRS morphology
Statistical analysis
Continuous variables were expressed as mean (SD) and categorical variables as percentages. Normality was tested using the Shapiro-Wilk test. For clinical characteristics that are continuous variables, comparison between two groups was performed using Student's t-test or the Wilcoxon rank sum test as appropriate. Dichotomous variables were compared with Fisher's exact test. Proportional hazard models and Kaplan -Meier time to first event curves were compared between groups. Multivariate analysis by the Cox-proportional hazards model was used to assess the impact of the LVLED on the clinical outcome. All pre-specified, clinically relevant variables such as age, gender, ischaemic cardiomyopathy (ICM), atrial fibrillation, diabetes, hypertension, serum creatinine, baseline NYHA class, and medications such as betablocker, angiotensin-converting enzyme (ACE) inhibitors, diuretics, digoxin, and aldosterone antagonists were tested in univariate analysis. Variables with P-values ,0.1 on univariate analysis were entered into the multivariate model. Stepwise selection was utilized to analyse covariates. The final model was restricted to three covariates based on the rule of thumb of 1 covariate per 10 events. In the final model, female gender was retained because of its clinical relevance and demonstration of it being a predictor of CRT outcomes in earlier studies. Long LVLED remained a significant predictor with a stable hazard ratio and standard error in all the tested models. Schoenfeld residuals were used to test for proportionality assumption. A two-sided P-value of ,0.05 was considered statistically significant. All analysis was done using STATA 12.1 (StataCorp, College Station, TX, USA)
Results
Baseline characteristics of the entire study cohort were the mean age of 67 + 12 years, baseline QRS duration was 156 + 28 ms, baseline LVEF of 23 + 7%, NYHA class III 83.5%, females 25%, and ischaemic cardiomyopathy, 62.5%. A LBBB was present in 57% (n ¼ 82) and non-LBBB in 43% (n ¼ 62). Among non-LBBB, 29% (n ¼ 18) had a right bundle branch block (RBBB) and 71% (n ¼ 44) had a non-specific intraventricular conduction delay (IVCD). Baseline characteristics by QRS morphology are shown in Table 1 and Supplementary material online, Table.
Baseline characteristics by QRS morphology
Even though LBBB and non-LBBB patients were comparable in terms of age, baseline renal function, hypertension, and LV internal dimensions, they differed in several key co-morbidities, namely coronary artery disease, ICM, percentage of coronary artery bypass (CABG) procedure, permanent atrial fibrillation, and diuretic use (Tables 1 and 2 ). These were densely prevalent in non-LBBB patients. However, non-LBBB cohort had fewer females, shorter QRS duration compared with the LBBB cohort.
Within the non-LBBB cohort, RBBB patients were older with longer QRS duration and relatively smaller LV internal dimensions when compared with patients with IVCD. Notably, RBBB patients had a higher burden of diabetes, hypertension, ischaemic cardiomyopathy, atrial fibrillation, and coronary artery bypass surgery.
Baseline QRS duration varied among LBBB (161 + 27 ms) and non-LBBB (152 + 29, P ¼ 0.06) patients. Even though QLV was longest in LBBB, it was comparable between RBBB and IVCD (87 ms in RBBB vs. 94 ms in IVCD, P ¼ NS). In addition, LV lead was most commonly located in the mid-ventricular-lateral segment in LBBB, RBBB, and IVCD groups. LBBB and non-LBBB groups were stratified based on the extent of an electrical delay, i.e. LVLED ≥50% and LVLED ,50%. Notably, stratified LVLED groups were comparable in their baseline characteristics (Table 2) .
Relationship between electrical delay and QRS duration by QRS morphology
The mean QRS duration was longer in the LBBB (161 + 27 ms) compared with non-LBBB (152 + 29 ms). As expected, the mean LVLED in the LBBB was longer compared with non-LBBB (73 + 25 vs. 61 + 21%, P ¼ 0.002). Within non-LBBB, IVCD had a mean LVLED of 63 + 23% and RBBB had a mean of 55 + 15% (P ¼ NS). An identical pattern was noted with QLV, which was longer in LBBB (118 + 47 ms) vs. RBBB (87 + 25 ms) vs. IVCD (94 + 41 ms) (P ¼ 0.004). QLV in RBBB and IVCD was comparable. QLV correlated linearly with QRS duration (r ¼ 0.52, P , 0.0001) in both LBBB and non-LBBB groups while LVLED (QLV corrected to QRS duration) did not (r ¼ 0.09, P ¼ 0.9). Of note, QLV, when corrected to QRS duration appears to better characterize electrical location of LV lead with respect to the overall ventricular activation sequence. For the rest of the analysis, QLV corrected to QRS duration (LVLED) was used.
The median QRS axis in LBBB patients was 2258 (2438-248), RBBB 2678 (2768 to 2448) and IVCD 2158 (2498-808). Among non-LBBB patients, left-axis deviation (LAD) was present in 54%, while in RBBB patients it was 82% and in IVCD it was 40% (P ≤ 0.001). Within the RBBB group 77% of patients had left-axis deviation along with wide upright R-wave in leads aVL or I suggestive of the left-sided conduction delay.
QRS Morphology, anatomical left ventricular lead location and left ventricular electrical delay
Left ventricular lead location in the long axis was predominantly located in mid-ventricular segment 56% (n ¼ 79) and lateral or posterolateral location 83% (n ¼ 116) in the short axis. Details of LV lead location by QRS morphology are described in Tables 1 and 2 .
In all QRS configurations, i.e. LBBB, RBBB, and IVCD, the LV lead was most commonly located in the mid-ventricular segment of the lateral or posterolateral wall. Apical lead location was less common in IVCD compared with the LBBB (12 vs. 25%, P ¼ 0.3). Overall, anatomically non-optimal LV lead locations (anterior, apical, and posterior) were uniformly distributed among LBBB and non-LBBB groups (28 vs. 27%, P ¼ 0.9). In the entire cohort, the mean LVLED was shorter in anterior (51 + 17%), posterior (62 + 23%) compared with lateral (70 + 23%) and posterolateral (71 + 24%) (P ¼ 0.2) although not statistically significant. There was no significant difference in the mean LVLED by LV lead location in the long axis (70 + 25% in basal vs. 68 + 25% in mid vs. 65 + 19% in apical ventricular segments, P ¼ 0.74).
Clinical outcomes
Primary outcome: time to first heart failure hospitalization
The primary outcome time to first HFH was examined during a follow-up period of 3 years. In the entire cohort, 33% (n ¼ 47) were hospitalized over 3 years: 43.5% in the non-LBBB group compared with 24% in the LBBB (P ¼ 0.015). In particular, patients who were hospitalized had a shorter mean LVLED (58 + 26%) compared with patients who were not (73 + 22%, P ¼ 0.01). Patients with the LBBB had a better event-free survival with respect to time to first HFH and composite outcome compared with non-LBBB (P ¼ 0.007 by the log-rank test) as depicted by the Kaplan -Meier method in Figures 2 and 3 .
In the LBBB cohort, patients with the LVLED ≥50% had fewer hospitalizations compared with the LVLED ,50% (17 vs. 53%, P ¼ 0.002). Kaplan-Meier survival curves showed a longer event-free survival with respect to time to first HFH in the LVLED ≥50% (P ¼ 0.008) ( Figure 4A) . Likewise, the LVLED had a similar impact in the non-LBBB cohort; specifically patients with the LVLED ≥50% had fewer hospitalizations (36%) compared with patients with the LVLED ,50 (61%, P ¼ 0. method demonstrated superior event-free survival with respect to time to first HF hospitalization in non-LBBB patients with the LVLED ≥50% (P ¼ 0.026 by the log-rank test) ( Figure 4A ). Within the non-LBBB group, RBBB patients with a longer LVLED (≥50%) had fewer hospitalizations (33%) compared with 83% (P ¼ 0.046) in patients with the LVLED ,50% ( Figure 5A ). In the IVCD group, HF hospitalization in patients with the LVLED ≥50% was 37.5% compared with 50% in the LVLED ,50% (P ¼ 0.45).
Composite endpoint
In the entire cohort, 42% (n ¼ 61) met with the composite outcome of all-cause mortality, HFH, LVAD implantation, and cardiac transplantation. A higher proportion (55%) in the non-LBBB met the criteria for the composite endpoint compared with 33% in the LBBB (P ¼ 0.008) consequently poorer event-free survival with respect to the composite outcome ( Figures 2B and 3B) .
In the LBBB cohort, patients with a longer LVLED fared better with fewer patients reaching the composite endpoint compared with those with a shorter LVLED (28 vs. 53%, P ¼ 0.049). In the non-LBBB, the composite outcome in the long LVLED was 45 vs. 78% in the short LVLED (P ¼ 0.020). Among the RBBB group, 41% in the long-LVLED group reached the composite endpoint compared with 100% in the short-LVLED group (P ¼ 0.017). Among the RBBB group, a longer LVLED translated into better survival with respect to the composite outcome as shown in Figures 4B and 5B. a long LVLED had a composite outcome of 47 vs. 66% in a short LVLED (P ¼ 0.2). Among IVCD patients, long-electrical delay did not result in statistically significant improvement in survival.
Predictors of clinical response
In univariate analysis of non-LBBB patients, the LVLED ≥50%, diabetes mellitus, and serum creatinine were significant predictors of HFH. In the adjusted multivariate Cox-proportional hazards model, the LVLED ≥50% remained a significant predictor of HF hospitalization with an HR of 0.34 (0.14-0.78, P ¼ 0.011) along with serum creatinine with an HR of 3.8 (1.7-8.5, P ¼ 0.001).
In a model predicting the composite outcome, longer LVLED and serum creatinine were significant univariate and multivariate predictors. A longer LVLED had an HR of 0.41 (0.19-0.85, P ¼ 0.019) and serum creatinine had an HR of 2.6 (1.5-4.6, P ¼ 0.001).
In patients with non-LBBB morphology and anatomically optimal LV lead location (lateral and posterolateral), patients with a longer LVLED had an improved survival free of HFH (37.5% in LVLED ≥50 vs. 61% in LVLED ,50, P ¼ 0.049 by the log-rank test) and improved survival with respect to the composite outcome (47.5% in LVLED ≥50 vs. 78% in LVLED ,50, P ¼ 0.022 by the log-rank test). Thus, a longer LVLED was associated with improved clinical outcomes within patients with anatomically optimal LV lead locations.
In the LBBB cohort, long LVLED, female gender, and aldosterone antagonists were statistically significant predictors of freedom from HFH and the composite outcome in univariate analysis and in multivariate analysis. The LVLED ≥50% was a significant predictor of time to HFH with an HR of 0.21 (0.08-0.53, P ¼ 0.001) as well as composite outcome with an HR of 0.38 (0.17-0.87, P ¼ 0.02) ( Table 3) .
Echocardiographic response
The echocardiographic response was defined as an improvement in the LVEF by 10%. The echo response was lower in non-LBBB (20%) vs. 45% (P ¼ 0.005) in LBBB. Within the LBBB morphology cohort, longer LVLED was associated with a significantly higher echocardiographic response (52% in long LVLED vs. 33% in a short LVLED, P ¼ 0.029). Similarly, patients with a longer LVLED in a non-LBBB benefited with a higher echo response compared with a shorter LVLED (24 vs.19%, P ¼ 0.03).
Discussion
In patients receiving CRT for advanced systolic heart failure and associated intraventricular conduction abnormality, LV lead placement in a region of a significant electrical delay (i.e. long LVLED) was associated with an improved event-free survival with respect to time to the first HF hospitalization and the composite outcome of all-cause mortality, HFH, LVAD implantation, and cardiac transplantation. Our study demonstrates for the first time that the electrical location of the LV lead is associated with improved clinical outcomes in patients with both non-LBBB and LBBB QRS morphologies. Notably, survival with respect to allcause mortality alone was not significantly higher among patients with long LVLED. The improved survival with respect to the composite outcome of all-cause mortality, HFH, LVAD implantation, and cardiac transplantation was driven by the improved freedom from HFH. However, our study was underpowered to detect any survival difference with respect to all-cause mortality.
Non-LBBB patients are sparsely represented in major clinical trials. The current evidence of the worse clinical outcome and poor reverse remodelling after CRT in non-LBBB patients is mostly derived from observational studies or post hoc analysis. For instance, in a meta-analysis of four randomized trials (COM-PANION, CARE-HF, MADIT-CRT, and RAFT) inclusive of 5356 patients, non-LBBB patients did not benefit from CRT. 16 Interestingly, in MADIT-CRT, non-LBBB (228/1281) patients (NYHA class II and I) had significant reverse remodelling that did not translate into reduction in clinical events. Although anatomical lead location (i.e. apical) was associated with a poor clinical outcome, the electrical location of the LV lead was not determined in this study. The SMART-AV study recently showed that the measurement of the electrical delay is a practical tool to individualize CRT delivery. This prospective substudy of 426 patients (LBBB 70%, IVCD 12%, and RBBB 13%) demonstrated that a QLV .95 ms was strongly associated with improved reverse remodelling and QOL improvement even after adjustment for baseline QRS morphology. 17 Evidently, non-LBBB patients with underlying cardiomyopathy may have the potential to benefit from CRT; with targeting the LV lead in a region of a significant electrical delay. The presence of mechanical dyssynchrony in different QRS morphologies was recently investigated in a study of 248 patients using speckle tracking radial strain analysis. Lateral, posterior, and inferior segments were the latest activated segments 73% of the time in all QRS morphology inclusive of LBBB, RBBB, and IVCD. 18 Targeting LV lead implantation to the site of latest mechanical activation has shown to improve the response. 19 Although this was not specifically evaluated by QRS morphology, it does make a case for individualized LV lead implantation strategy to improve the CRT response. The low CRT response rates reported for non-LBBB patients in most studies are reflective of the heterogeneity in the mechanical dyssynchrony distribution, where the anatomical approach of targeting the lateral free wall does not work well enough. Intra-procedural LVLED assessment (although retrospectively analysed in our study) with targeted LV lead placement may serve to be a valuable practical tool in enhancing the clinical response in this subset of CRT patients.
Rationale for cardiac resynchronization therapy in left bundle branch block and non-left bundle branch block: role of activation sequence
Non-LBBB patients are fundamentally different in their activation sequence from LBBB patients. The LBBB itself is a very heterogeneous conduction disorder with a characteristic U-shaped activation sequence, with early RV activation, ultimately ending in the basal region of lateral or posterolateral wall, near mitral annulus. 20 Atrio-biventricular pacing generates two activation sequences, first one at the endocardial RV apex and the other usually epicardial lateral surface, which in turn collide in a variable fashion depending on substrate and conduction abnormalities. In the LBBB, pre-excitation of the delayed area shortens LV activation and improves the haemodynamic response. 20, 21 While in RBBB, there is delayed RV activation, with relatively early LV activation. Seemingly, LV pacing may not be beneficial in RBBB patients. Nevertheless, electro anatomical mapping 22 of patients with the RBBB pattern has demonstrated a significant left ventricular conduction delay (especially in wide QRS situations), albeit with wide variability. 23 An ECG pattern 'RBBB masking LBBB' characterized by broad, slurred, sometimes notched R-wave in leads I and aVL along with LAD and RBBB may help identify these patients with a left-sided conduction delay. 20 Most of our RBBB patients (n ¼ 14/18) had LAD with R-wave in aVL or I. Even though this finding may explain the improved outcomes with a longer LVLED in RBBB patients, further interpretation of this observation is limited due to a small number of patients. In IVCD patients, conduction disturbances can be extremely variable, usually in both the right and left conduction system. There was no significant improvement in outcomes in patients with a long-electrical delay in the IVCD group. Of note, patients with IVCD morphology had a higher incidence of comorbidities, probably contributing to the worse clinical outcome compared with the LBBB population.
Effect of co-morbidities on cardiac resynchronization therapy response by QRS morphology
Compared with LBBB, patients with non-LBBB QRS morphology have a higher burden of coronary artery disease, atrial fibrillation, ischaemic cardiomyopathy, higher percentage of CABG, and a greater use of diuretics possibly reflecting greater severity of heart failure. A few studies reported a higher incidence of right ventricular dysfunction, elevated pulmonary artery systolic pressure, and right heart failure associated with RBBB patients. 24 Given the higher burden of co-morbidities, it is not surprising that non-LBBB patients do not demonstrate a similar extent of survival benefit seen in LBBB patients, although they do exhibit some extent of reverse remodelling. The distribution of co-morbidities in our study is similar to published report on 15 000 Medicare beneficiaries, 24 where RBBB patients experienced higher adverse clinical outcomes compared with LBBB.
Limitations
This study was conducted at a single centre, hence limiting its generalizability. Importantly, however, our study cohort is truly representative of a real-world population with advanced systolic heart failure. In multivariate analysis, a parsimonious model was generated because of a small sample size; this may have an impact on the strength of association of LVLED and clinical outcome. Our study did not characterize right ventricular function, which may have had an impact on the CRT outcome. Although the LVLEDs were recorded prospectively, they were not necessarily a determinant of the final LV lead placement at the time of the implant. Left ventricular lead placement was at the discretion of the implanting physician, and was usually determined by anatomical constraints, pacing thresholds and intent to avoid phrenic pacing. As this is a retrospective study, the impact of certain factors such as physician discretion and the implanting practice of proactively targeting the area of an electrical delay cannot be completely accounted for. Although the LV lead location was not controlled for in this study, the distribution of LV lead location between different QRS morphologies was comparable, with the majority of the lead placements along the LV free wall in the midventricular region. Given the variability in coronary venous anatomy, finding a suitable vein with an acceptable LVLED could potentially increase procedure times and radiation exposure. Of note, although patients included in the study were all followed systematically within our hospital system, it is possible that on account of this not being a prospective randomized clinical study, hospitalizations for heart failure could be underestimated.
Implications
There is considerable heterogeneity in the electrical activation pattern and distribution of dyssynchrony in patients receiving CRT. In particular, patients with non-LBBB morphology have a poorer clinical outcome, and seemingly the one-size fit all anatomical LV lead placement approach does not work well in this cohort.
Our results demonstrate that getting the lead to a region of the heart that is delayed in its electrical activation may translate into better outcomes. It seems reasonable to speculate, that we need to individualize our lead placement and especially in the non-LBBB cohort using the venous anatomy to get to a region of an electrical delay (LVLED .50% of the QRS duration) may be more valuable than conventional targeting of the lateral free wall. This, however, will need to be validated prospectively.
Conclusion
In patients receiving CRT for advanced systolic heart failure with conduction system disease, LV lead placed in a region of delayed electrical activation (measured by LVLED) was significantly associated with improved clinical outcomes in non-LBBB and LBBB patients. This study shows for the first time that LV lead location may positively impact the clinical outcome in non-LBBB patients.
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